Cowen’s healthcare analyst Phil Nadeau came out with a research note on Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA), following the company’s earnings release for the fourth-quarter.
Cowen’s healthcare analyst Phil Nadeau is weighing in with a few insights on Achillion Pharmaceuticals (NASDAQ:ACHN), following new trial results which demonstrated that a combination of the …
In a research report sent to investors, Cowen analyst Phil Nadeau maintained a Market Perform rating on Ariad Pharmaceuticals (NASDAQ:ARIA) with a $4.50 …
Cowen analyst Phil Nadeau reiterated an Outperform rating on GW Pharmaceuticals (NASDAQ:GWPH) with a price target of $110, following the news that the company’s first Phase …
In a research report sent to investors today, Cowen analyst Phil Nadeau maintained an Outperform rating on Gilead Sciences (NASDAQ:GILD) with a price …
Cowen analyst Phil Nadeau maintained an Outperform rating on Dynavax Technologies (NASDAQ:DVAX) and raised his price target to $60 (from $6) to reflect the recent 10:1 reverse …
Cowen analyst Phil Nadeau reiterated an Outperform rating on GW Pharmaceuticals (NASDAQ:GWPH) with a price target of $110, as the company announced financial …
